Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for protein-protein interfaces.
Fig. 1. The sreening workflow of Receptor.AI
This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P26842
UPID:
CD27_HUMAN
Alternative names:
CD27L receptor; T-cell activation antigen CD27; T14; Tumor necrosis factor receptor superfamily member 7
Alternative UPACC:
P26842; B2RDZ0
Background:
The CD27 antigen, known by alternative names such as CD27L receptor, T-cell activation antigen CD27, T14, and Tumor necrosis factor receptor superfamily member 7, plays a pivotal role in the immune system. It functions as a receptor for CD70/CD27L, contributing to the survival of activated T-cells and potentially playing a role in apoptosis through its association with SIVA1.
Therapeutic significance:
CD27 antigen's involvement in Lymphoproliferative syndrome 2, a disorder characterized by a spectrum of immune deficiencies including persistent EBV viremia and hypogammaglobulinemia, underscores its therapeutic significance. Targeting CD27 could offer novel treatment avenues for managing this complex immunodeficiency and its life-threatening complications.